The GLP-1 receptor (GLP1R) mediates the actions of glucagon-like peptide 1¹¹ glucagon-like peptide 1
GLP-1 is an incretin hormone that stimulates insulin secretion, slows gastric emptying, and suppresses appetite, one of the body's most important metabolic hormones. GLP1R is also the target of blockbuster medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). The rs1042044 variant causes a leucine-to-phenylalanine substitution at position 260, located in intracellular loop 2²² intracellular loop 2
the region of the receptor inside the cell that couples to G proteins and downstream signaling molecules of the receptor protein.

The Mechanism

The Leu260Phe substitution sits in the intracellular signaling domain of the GLP-1 receptor, where it can influence how the receptor communicates with downstream G proteins and beta-arrestins after ligand binding. Functional studies from the CATIE trial showed that cells expressing the Leu260 variant (A allele) display significantly reduced cell surface protein expression³³ significantly reduced cell surface protein expression
approximately 30-40% of wild-type levels but paradoxically show numerically greater calcium mobilization per receptor, suggesting each individual receptor may signal more efficiently. This creates a complex pharmacological profile: fewer receptors on the surface, but each one potentially more active.

The variant's location in intracellular loop 2 affects the receptor's interaction with intracellular signaling cascades including the cAMP pathway⁴⁴ cAMP pathway
cyclic AMP is the primary second messenger activated by GLP-1 receptor signaling and calcium-dependent insulin secretion. A Russian study in 174 subjects found that CA heterozygotes had significantly lower postprandial C-peptide and insulin responses compared to CC homozygotes, confirming reduced insulin secretory capacity in A allele carriers.

The Evidence

The strongest pharmacogenomic evidence comes from the CATIE antipsychotic trial⁵⁵ CATIE antipsychotic trial
Brandl EJ et al. GLP1R haplotypes correlate with altered response to multiple antipsychotics. Schizophr Res, 2015, which studied 597 Caucasian subjects across five antipsychotic medications. The GLP1R haplotype uniquely tagged by the rs1042044 Leu260 allele was associated with significantly better response to olanzapine (Cohen's d=-0.62, p=0.002) and risperidone (d=-0.62, p=0.006), but worse response to perphenazine (p=0.03) and ziprasidone (d=0.81, p=0.003). A recessive genetic model provided the best fit, meaning two copies of the A allele are needed for the full effect.

Beyond antipsychotic response, the variant has been linked to HPA axis function⁶⁶ HPA axis function
the hypothalamic-pituitary-adrenal axis controls cortisol secretion and stress responses. In a study of 77 preschool-aged children, those homozygous for the Phe260 allele (CC genotype) had significantly higher morning salivary cortisol levels (p=0.008), suggesting the GLP-1 receptor plays a role in stress hormone regulation from early life ⁷⁷ Beinfeld MC et al. J Psychiatr Res, 2010.

An Egyptian case-control study of 160 subjects found the AA genotype was associated with a 4.5-fold increased risk of papillary thyroid cancer ⁸⁸ Ibrahim AA et al. Gene, 2022, with higher GLP-1R mRNA and protein expression in tumour tissue of AA carriers. In Chinese postmenopausal women, the A allele carried a 2.76-fold increased risk of osteoporosis, with a significant gene-gene interaction with the GLP1R variant rs2268641 ⁹⁹ Xu et al. PLOS ONE, 2024.

Practical Implications

For most people, this variant's primary clinical relevance lies in antipsychotic pharmacogenomics. If you are prescribed olanzapine or risperidone, the AA genotype predicts better treatment response. Conversely, perphenazine and ziprasidone may be less effective. The variant does not predict antipsychotic-induced weight gain.

The associations with bone density and thyroid cancer are from smaller studies that require replication in larger cohorts before clinical action is warranted. However, the consistent direction of effects across multiple tissues (pancreas, brain, bone, thyroid) supports genuine functional significance of this receptor variant.

Interactions

The rs1042044 variant sits on the same gene as rs6923761 (Gly168Ser)¹⁰¹⁰ rs6923761 (Gly168Ser)
the most studied GLP1R pharmacogenomic variant, affecting GLP-1 agonist drug response, and the two variants tag different GLP1R haplotypes. In the CATIE trial, rs6923761 tagged haplotype 2 (associated with altered antipsychotic response via a dominant model), while rs1042044 tagged haplotype 1 (recessive model). These haplotypes have independent and sometimes opposing effects on drug response. A significant interaction between rs1042044 and rs2268641 has been documented for osteoporosis risk in Chinese postmenopausal women, where neither variant alone fully explains the effect.

Every time you eat, your gut releases a hormone called GIP (glucose-dependent insulinotropic polypeptide)¹¹ GIP (glucose-dependent insulinotropic polypeptide)
GIP is secreted by K-cells of the small intestinal mucosa in response to glucose and fat ingestion; it accounts for roughly half of the incretin effect that amplifies meal-induced insulin secretion that signals your pancreas to release insulin. The GIPR gene encodes the receptor that detects this signal. rs10423928 is a common variant in an intron of GIPR that subtly disrupts how the receptor is assembled from its mRNA, with a paradoxical metabolic outcome: reduced insulin response but a leaner body.

The Mechanism

rs10423928 sits within an intron of GIPR, but its functional impact is mechanistic, not trivial. The A allele shifts the balance of GIPR mRNA splice variants: it reduces the proportion of transcripts that include exon 9, which encodes part of the seven-helix transmembrane domain required for a fully functional, membrane-anchored receptor. In adipose tissue from A-allele carriers²² In adipose tissue from A-allele carriers
Müller et al. Diabetes 2011 — analysis of adipose biopsies from the Botnia and Danish Twin cohorts showed reduced exon-9-containing isoform abundance in A allele carriers, the proportion of functional GIPR on the cell surface is modestly but consistently reduced.

The net result is a blunted incretin response specifically after oral glucose or fat ingestion. When A-allele carriers receive glucose by mouth, the GIP released from the gut cannot fully activate their pancreatic beta-cell GIPR, so insulin secretion falls short. Crucially, when glucose is given intravenously — bypassing the GIP signal entirely — insulin secretion is normal. This confirms the defect is specifically in the GIP-mediated incretin pathway, not in basal beta-cell function.

The same reduced GIPR function in adipose tissue has an unexpected upside: GIP normally promotes fat storage and adipogenesis. With less receptor signaling, A-allele carriers accumulate less adipose tissue, resulting in lower BMI, reduced fat mass, and lower lean body mass.

rs10423928 is in near-perfect linkage disequilibrium (r²≈0.99) with the missense variant rs1800437 (Glu354Gln)³³ rs1800437 (Glu354Gln)
The E354Q change sits in exon 10 of GIPR and reduces receptor signaling by increasing desensitization and downregulation. The two variants are so tightly co-inherited that they functionally represent the same causal signal, operating through both splicing and protein-level mechanisms.

The Evidence

The foundational study was a GWAS meta-analysis by Saxena et al. in Nature Genetics 2010⁴⁴ GWAS meta-analysis by Saxena et al. in Nature Genetics 2010
Saxena R et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nature Genetics 2010 involving 15,234 discovery and up to 30,620 total nondiabetic participants. The A allele was associated with higher 2-hour glucose (beta=0.09 mmol/L per allele, p=2×10⁻¹⁵), lower insulinogenic index (p=1×10⁻¹⁷), and reduced incretin effect (p=4.3×10⁻⁴) in 804 individuals tested with both oral and intravenous glucose challenges.

A follow-up study in 53,730 nondiabetic and 2,731 diabetic subjects⁵⁵ 53,730 nondiabetic and 2,731 diabetic subjects
Müller et al. Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 2011 confirmed impaired GIP-stimulated insulin secretion and, strikingly, found that A-allele carriers had approximately 2.9 kg lower lean body mass and reduced fat mass — with the BMI-lowering effect nearly completely offsetting the insulin-secretion impairment in terms of net type 2 diabetes risk.

The Malmö Diet and Cancer cohort⁶⁶ Malmö Diet and Cancer cohort
Renström F et al. Genetic variation in the GIPR modifies the association between carbohydrate and fat intake and type 2 diabetes risk. JCEM 2012 (24,840 subjects followed 12 years) revealed a striking gene-diet interaction: AA homozygotes eating a high-fat, low-carbohydrate diet had a 69% lower T2D risk compared to those eating low-fat; TT homozygotes showed 23% lower T2D risk from a high-carbohydrate, low-fat diet. The macronutrient that bypasses impaired GIP-mediated signaling (fat rather than carbohydrate as the main fuel) aligns with the reduced incretin effect in A-allele carriers.

Practical Actions

For A-allele carriers (AT or AA genotypes), the impaired GIP-mediated insulin response means that high-carbohydrate meals are less efficiently handled — the insulin surge that normally dampens post-meal glucose is blunted. Shifting calories toward fat (unsaturated and omega-3 rich) and moderating carbohydrate intake — particularly refined carbohydrates and sugars — aligns with both the mechanistic evidence and the Malmö cohort findings. Monitoring postprandial glucose (particularly the 2-hour mark after meals) provides direct feedback on how this genotype affects meal tolerance.

The variant is also pharmacogenomically relevant: tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor co-agonist that works partly through GIPR. Reduced receptor function from rs10423928 may blunt the GIPR component of tirzepatide's effect, though direct clinical evidence in carriers is not yet published.

Interactions

rs10423928 acts in the incretin pathway alongside GLP-1R variants. The GLP-1R variant rs6923761 (Gly168Ser) affects the parallel incretin arm — GLP-1 signaling — and has been associated with differential responses to GLP-1-based therapies. Carriers of reduced-function variants in both GIPR (rs10423928 A allele) and GLP-1R may have compounded impairment of the overall incretin effect, increasing postprandial glucose excursions. A compound action covering this interaction would be warranted if clinical evidence for combined effects emerges.

Within the GIPR locus, rs10423928 and rs1800437 (E354Q) are in r²≈0.99 LD and co-segregate as a functional haplotype. The related intronic variant rs2302382 has been associated with T2DM risk in Middle Eastern populations and is likely part of the same haplotype block.

Your body cannot continuously synthesize tetrahydrobiopterin (BH4)¹¹ tetrahydrobiopterin (BH4)
BH4: a pteridine cofactor essential for aromatic amino acid hydroxylases and nitric oxide synthases from scratch fast enough to meet demand. Instead, it relies on QDPR — quinoid dihydropteridine reductase — to continuously regenerate BH4 from its spent, oxidized form. Every time a dopamine, serotonin, or nitric oxide molecule is synthesized, BH4 is consumed and converted to quinonoid dihydrobiopterin (qBH2). QDPR's job is to reduce qBH2 back to active BH4, completing the recycling loop. Without efficient recycling, BH4 pools deplete, and the enzymes that depend on it — tyrosine hydroxylase, tryptophan hydroxylase, phenylalanine hydroxylase, and all three nitric oxide synthases — begin to stall.

The Mechanism

rs10483099 is an intronic variant in the QDPR genomic region. Intronic variants can influence gene expression through effects on splicing regulatory elements, transcription factor binding sites within introns, or regulatory RNA interactions. When QDPR output is reduced, the BH4/BH2 ratio shifts toward the oxidized form. This has a dual consequence: first, neurotransmitter-synthesizing enzymes lose their cofactor supply; second, uncoupled nitric oxide synthase ²² eNOS "uncoupled" from BH4 produces superoxide instead of NO — converting a vasodilatory enzyme into a source of oxidative stress switches from generating protective nitric oxide to generating superoxide, a reactive oxygen species.

A 2023 study revealed that QDPR also processes quinonoid dihydrofolate as a second substrate³³ quinonoid dihydrofolate as a second substrate
Shimizu et al. 2023 — QDPR accepts qDHF alongside qBH2, placing the enzyme at the junction of BH4 and folate cycles. This means reduced QDPR activity can impair both pteridine recycling and folate metabolite handling, situating QDPR at the crossroads of two critical one-carbon metabolism pathways.

The Evidence

Mouse knockout studies provide the clearest mechanistic evidence. Qdpr⁻/⁻ mice develop mild hyperphenylalaninemia and brain monoamine deficiency⁴⁴ Qdpr⁻/⁻ mice develop mild hyperphenylalaninemia and brain monoamine deficiency
Takazawa et al. 2022 — QDPR knockout shows monoamine depletion and enhanced fear responses; phenylalanine restriction restores neurotransmitter levels, accompanied by enhanced fear responses to aversive stimuli — a behavioral phenotype consistent with serotonergic and dopaminergic disruption. A separate knockout study demonstrated that QDPR-deficient platelets store and release significantly less serotonin⁵⁵ QDPR-deficient platelets store and release significantly less serotonin
Nakamura et al. 2022 — Qdpr⁻/⁻ mice show suppressed platelet aggregation from reduced serotonin storage, reversed by 5-HTP supplementation, with platelet aggregation defects reversed by serotonin precursor supplementation.

In human populations, a comprehensive review of 1,100+ patients with BH4 deficiency⁶⁶ a comprehensive review of 1,100+ patients with BH4 deficiency
Himmelreich et al. 2021 — five-gene BH4 pathway review covering 800+ allelic variants in pediatric neurotransmitter disorders database across five pathway genes established that QDPR deficiency produces a distinct phenotype: hyperphenylalaninemia plus monoamine neurotransmitter deficiency, which distinguishes it from SPR deficiency (no hyperphenylalaninemia) and GCH1 deficiency (primarily dystonic phenotype).

The pharmacological angle is also relevant: QDPR inhibition synergizes with methotrexate⁷⁷ QDPR inhibition synergizes with methotrexate
Takahashi et al. 2024 — QDPR inhibitor compound 9b + methotrexate significantly oxidizes BH4/BH2 ratio in liver, immune, and neuronal cells to oxidize intracellular BH4 pools across liver, immune, and neuronal cell types, confirming QDPR's central role in maintaining the BH4/BH2 ratio under pharmacological stress.

For rs10483099 specifically, the T allele is common (approximately 20% globally, reaching 36% in South Asian populations) and carries no ClinVar significance annotation. The evidence for functional impact at this specific locus is emerging — based on pathway biology rather than direct functional studies of this variant. Individuals carrying one or two T alleles may have modestly reduced QDPR expression in relevant tissues, warranting attention to cofactor support.

Practical Actions

Supporting the BH4 recycling pathway involves ensuring adequate supply of nutrients that feed into BH4 synthesis and reduce oxidative BH4 loss. Folate (as methylfolate) and riboflavin support the dihydrofolate reductase (DHFR) salvage pathway that can partially compensate for impaired QDPR recycling. Dietary tyrosine and tryptophan ensure that neurotransmitter-synthesizing enzymes are not substrate-limited when cofactor availability is borderline. Monitoring homocysteine provides an indirect window into one-carbon metabolism efficiency, which intersects with BH4 recycling through QDPR's folate substrate activity.

Interactions

This variant sits within the BH4 pathway, which includes GCH1 (BH4 synthesis upstream), PTS and SPR (biosynthesis intermediates), and QDPR (recycling). The MTHFR C677T variant (rs1801133) reduces methylfolate availability independently, and both impairments can converge on insufficient one-carbon pool support. The NOS3 Glu298Asp variant (rs1799983) affects the enzyme that depends on BH4 for nitric oxide production; carriers of both rs10483099 T and rs1799983 risk alleles may face compounded pressure on the NO synthesis pathway. Methotrexate inhibits DHFR and effectively blocks the alternative folate-to-BH4 salvage route, making T carriers on methotrexate more vulnerable to BH4 depletion.

CYP17A1¹¹ CYP17A1
cytochrome P450 17α-hydroxylase/17,20-lyase — the enzyme that performs two sequential reactions in steroid hormone synthesis: first converting pregnenolone and progesterone to their 17-hydroxy forms, then cleaving the two-carbon side chain to produce DHEA and androstenedione sits at the branch point between the mineralocorticoid and sex steroid pathways. When CYP17A1 works normally, the adrenal glands and gonads can produce cortisol and sex hormones. When it is impaired, the steroid synthesis pipeline is diverted: mineralocorticoid precursors accumulate (causing hypertension and low potassium), while sex steroids — testosterone in males, estrogens in females — cannot be made in adequate quantities. The rs104894137 Pro342Thr variant is a rare missense mutation that reduces CYP17A1 enzyme activity to roughly 40–45% of normal. This partial impairment produces a milder clinical picture than complete deficiency, but the consequences for steroidogenesis, blood pressure, and reproductive capacity are real and actionable.

The Mechanism

The p.Pro342Thr substitution²² p.Pro342Thr substitution
a C-to-A transversion in exon 6 of CYP17A1, c.1024C>A on the coding strand; gene is on the minus strand of chr10, so the plus-strand change is G>T at position 102,832,626 (GRCh38) replaces a rigid proline residue at position 342 — within the heme-binding and substrate-positioning region of the enzyme — with the more flexible threonine. The conformational consequence is partial disruption of the active site geometry without destroying the protein itself: expression of the Pro342Thr mutant in COS-1 cells produces a normal amount of immunodetectable P450-17α protein, but both the 17α-hydroxylase and 17,20-lyase enzymatic activities are reduced to 40–45% of those of the wild-type enzyme³³ expression of the Pro342Thr mutant in COS-1 cells produces a normal amount of immunodetectable P450-17α protein, but both the 17α-hydroxylase and 17,20-lyase enzymatic activities are reduced to 40–45% of those of the wild-type enzyme. This "partial loss of function" phenotype means cortisol synthesis is impaired but not abolished, mineralocorticoid precursors (11-deoxycorticosterone, corticosterone) accumulate in excess of what ACTH suppression can prevent at baseline, and sex steroid synthesis is reduced but may allow some secondary sexual development — particularly in females with partial 17-OHD, where residual ovarian estrogen output can be sufficient for some pubertal changes. The original clinical report establishing this variant found it in compound heterozygosity with a nonsense mutation (Arg239*) in a 46,XY male with ambiguous external genitalia, demonstrating that even 40–45% residual lyase activity is insufficient for complete male virilization.

The Evidence

The foundational study characterizing Pro342Thr was Ahlgren et al. 1992 in the Journal of Clinical Endocrinology & Metabolism⁴⁴ Ahlgren et al. 1992 in the Journal of Clinical Endocrinology & Metabolism
Compound heterozygous mutations (Arg 239→stop, Pro 342→Thr) in the CYP17 gene lead to ambiguous external genitalia in a male patient with partial combined 17α-hydroxylase/17,20-lyase deficiency. JCEM 74(3):667–672. The patient was a 46,XY individual with ambiguous genitalia who was compound heterozygous: one allele (maternal) carried the truncating Arg239* mutation, the other (paternal) carried Pro342Thr. Site-directed mutagenesis of the Pro342Thr allele into human CYP17 cDNA and expression in COS-1 cells demonstrated that this single amino acid change is sufficient to reduce both hydroxylase and lyase activities to 40–45% of normal, confirming it as the molecular cause of partial enzyme impairment. The study also established a functional threshold: greater than 20% of normal 17,20-lyase activity is required for complete male virilization, illustrating why partial deficiency produces ambiguous rather than female-typical genitalia in 46,XY.

ClinVar classifies rs104894137 as Pathogenic for 17-alpha-hydroxylase/17,20-lyase deficiency, combined partial (RCV000001856)⁵⁵ Pathogenic for 17-alpha-hydroxylase/17,20-lyase deficiency, combined partial (RCV000001856), with a second submission of Likely-Pathogenic. OMIM records this as allelic variant 609300.0007 in the CYP17A1 gene entry.

The clinical consequences of partial 17α-hydroxylase deficiency in 46,XX females were further characterized in a 2022 Frontiers in Endocrinology cohort of 8 patients⁶⁶ 2022 Frontiers in Endocrinology cohort of 8 patients: most presented with oligomenorrhea or primary amenorrhea as the sole symptom, with mildly elevated FSH, suppressed testosterone, and elevated progesterone. The condition is frequently under-diagnosed because cortisol deficiency may be mild and hypertension may be absent or modest in partial forms. A 2023 study of ART outcomes in five women with CYP17A1 deficiency⁷⁷ 2023 study of ART outcomes in five women with CYP17A1 deficiency found that persistently elevated progesterone during ovarian stimulation prevents endometrial receptivity, necessitating a freeze-all strategy; frozen embryo transfer after GnRH agonist plus dexamethasone suppression of progesterone achieved four live births.

Practical Actions

Homozygous carriers of Pro342Thr or compound heterozygotes combining Pro342Thr with a second loss-of-function CYP17A1 allele have a confirmed steroidogenic defect. The cornerstones of management are glucocorticoid replacement to suppress ACTH-driven mineralocorticoid excess (treating hypertension and hypokalemia), sex steroid replacement at puberty and throughout adulthood, and — for women who want to conceive — specialist-supervised IVF using protocols that suppress endogenous progesterone before embryo transfer. Heterozygous carriers have 50–75% residual enzyme activity (one normal allele + one Pro342Thr allele) and are not expected to have clinical 17-OHD, but their children are at risk if the partner also carries a CYP17A1 pathogenic variant.

Blood pressure, serum potassium, and a full adrenal steroid profile are the priority tests for individuals confirmed to carry biallelic CYP17A1 pathogenic variants. Even in partial deficiency, hypertension and hypokalemia may be mild or intermittent and are easily missed without systematic measurement.

Interactions

Rs104894136 (Arg239*) is the nonsense allele that was found on the complementary chromosome in the original 1992 compound heterozygous patient; together with Pro342Thr it produces partial rather than complete deficiency because Pro342Thr still allows ~40–45% residual CYP17A1 activity. Two complete loss-of-function alleles (e.g., Arg239* + Arg239*) produce the complete form of 17-OHD with more severe phenotype: sexual infantilism, severe hypertension, and marked hypokalemia. The partial vs. complete phenotype distinction thus depends on which CYP17A1 alleles are co-inherited.

The common regulatory polymorphism rs743572 (CYP17A1 5′-UTR T>C) is sometimes measured in the context of cancer and hormonal conditions, but is distinct from this coding deficiency allele and does not cause enzyme impairment.

The heart's ability to pump depends on a precisely timed molecular switch inside every muscle fiber. Tropomyosin¹¹ Tropomyosin
A coiled-coil protein that winds along actin filaments in the sarcomere, blocking or exposing myosin binding sites in response to calcium signals sits at the center of this switch. In the resting heart, tropomyosin physically blocks myosin from grabbing actin. When calcium floods in during a heartbeat, tropomyosin pivots, exposing binding sites and triggering contraction. The TPM1 D175N variant — a single amino acid swap at position 175 of the alpha-1 chain — shifts this pivot point toward the "open" position even when calcium is still low, causing the heart to contract too readily, too forcefully, and eventually to remodel in dangerous ways.

The Mechanism

TPM1 encodes the alpha-tropomyosin chain²² alpha-tropomyosin chain
One of the two major sarcomeric tropomyosin isoforms; TPM1 is the cardiac-dominant form while TPM2 predominates in slow skeletal muscle, the primary regulatory component of the cardiac thin filament. At position 175, the normal aspartate residue (D) forms ionic interactions that hold tropomyosin in the blocked conformation at low calcium. The D175N substitution (G>A on chromosome 15, GRCh38: chr15:63060899) replaces this negatively charged aspartate with the neutral asparagine, weakening the restraint on tropomyosin's movement.

The result, demonstrated directly by Borovikov et al. using fluorescence-labeled thin filaments³³ Borovikov et al. using fluorescence-labeled thin filaments
The team incorporated Asp175Asn tropomyosin into isolated muscle fibers and tracked positional changes during the ATPase cycle, is that D175N tropomyosin stays shifted toward the open state throughout the contraction cycle, increasing the affinity of myosin for actin and allowing more cross-bridges to attach at any given calcium concentration. Calcium sensitivity of the thin filament rises — the heart contracts harder per unit of calcium signal. Over years, hypercontractility drives hypertrophic remodeling⁴⁴ hypertrophic remodeling
Asymmetric thickening of the left ventricular wall, particularly the interventricular septum, the cardinal anatomical feature of HCM, diastolic dysfunction, and eventually outflow tract obstruction or arrhythmia.

The Evidence

D175N is one of the best-characterized pathogenic tropomyosin variants in cardiology. It was classified by ClinVar as Pathogenic with a two-star review ("criteria provided, multiple submitters, no conflicts") across 22 submitting laboratories, including GeneDx, Blueprint Genetics, Invitae, and Color Diagnostics.

In Finland, D175N is a founder mutation⁵⁵ founder mutation
A variant that entered a population from a small number of ancestors and is now found at higher frequency than the global average due to population expansion from a bottleneck with geographic clustering in central and western Finland. Jääskeläinen et al. (2013)⁶⁶ Jääskeläinen et al. (2013)
Screening of 306 unrelated Finnish HCM patients from a catchment area of ~4 million people identified D175N in 6.5% of cases; an earlier regional study found it in 11% of HCM patients in eastern Finland, where it accounted for a substantial fraction of all diagnoses alongside five other founder mutations.

Imaging studies demonstrate the functional impact directly. Sipola et al. (Radiology, 2005)⁷⁷ Sipola et al. (Radiology, 2005)
Cine MRI in 24 D175N carriers vs 17 healthy controls, mean age 42 found that the proportion of hypokinetic myocardial segments was 37% in carriers versus 12% in controls (p < 0.001), and that the severity of contractile impairment independently predicted both LV mass (R² = 0.42) and maximal wall thickness (R² = 0.48). More recent genotype-outcome data from Conde et al. (2025)⁸⁸ Conde et al. (2025)
Retrospective cohort of 77 genotyped HCM patients with cardiac MRI, collected 2018–2024 found that thin filament variants — the class that includes TPM1 D175N — were associated with an 80% rate of non-sustained ventricular tachycardia and a 4.4-fold increased risk of major adverse cardiovascular events compared to mutation-negative HCM.

The nationwide FinHCM study (2019)⁹⁹ FinHCM study (2019)
382 unrelated index patients, 482 total participants including relatives, followed longitudinally found annual all-cause mortality of 1.70% among HCM patients carrying sarcomere mutations, roughly double the 0.87% rate in matched general population. Sudden cardiac death events were rare (n=8) but independent risk factors included greater LV wall thickness and systolic dysfunction.

Practical Actions

Because D175N acts in an autosomal dominant fashion, a single copy is sufficient to cause disease. Approximately 50% of first-degree relatives of an affected individual will carry the variant. Cascade genetic testing of all first-degree relatives (parents, siblings, children) is the cornerstone of management — relatives who test negative require no further cardiac surveillance for this variant, while those who test positive enter a monitoring program.

For carriers, management follows ESC and ACC/AHA hypertrophic cardiomyopathy guidelines¹⁰¹⁰ ESC and ACC/AHA hypertrophic cardiomyopathy guidelines
European Society of Cardiology 2023 HCM guidelines and ACC/AHA 2020 guidelines. Annual or biennial echocardiography and periodic Holter monitoring are standard. ICD implantation decisions are individualized using a formal SCD risk calculator (ESC HCM Risk-SCD score, which considers LV thickness, family SCD history, unexplained syncope, non-sustained VT, and LV outflow gradient). The phenotype in D175N carriers spans from subclinical hypertrophy to significant obstruction and arrhythmia, making serial monitoring essential.

Early-stage carriers may show the hypermetabolic compensatory state documented by PET imaging before overt hypertrophy emerges. This window represents an opportunity to establish specialist follow-up and baseline imaging before structural changes progress.

Interactions

HCM caused by D175N follows the "final common pathway" hypothesis: multiple sarcomere gene variants converge on the same phenotype via different mechanisms. Compound or double heterozygosity — carrying D175N alongside a pathogenic variant in MYH7 (beta-myosin heavy chain), MYBPC3 (cardiac myosin-binding protein C), or other sarcomere genes — is documented in individual cases and generally associated with more severe, earlier-onset disease. The FinHCM cohort included patients with multiple pathogenic sarcomere variants who showed accelerated hypertrophy and higher SCD risk. When cascade testing reveals that a family member carries both D175N and a second sarcomere variant, subspecialist referral for intensified surveillance is warranted.

Deep inside your intestinal lining, immune sentinel cells continuously survey the bacterial population that colonizes your gut. NOD2 (nucleotide-binding oligomerization domain-containing protein 2)¹¹ NOD2 (nucleotide-binding oligomerization domain-containing protein 2)
an intracellular pattern-recognition receptor expressed in intestinal epithelial cells, Paneth cells, and monocytes; detects muramyl dipeptide (MDP), a fragment of bacterial cell-wall peptidoglycan, to trigger NF-κB-mediated antimicrobial defense is the sentinel's core machinery. NOD2 was identified in 2001 as the first Crohn's disease susceptibility gene²² identified in 2001 as the first Crohn's disease susceptibility gene
discovered through positional cloning of the IBD1 locus on chromosome 16q12 by Hugot et al. and independently by Ogura et al., and it remains the single strongest genetic risk factor for this condition.

rs104895467 encodes the N852S substitution — asparagine replaced by serine at position 852 in the protein's leucine-rich repeat (LRR) domain³³ leucine-rich repeat (LRR) domain
the C-terminal sensing region of NOD2 that makes direct contact with muramyl dipeptide; mutations in this domain are the mechanistic basis for all three major Crohn's disease NOD2 variants. This is a rare variant globally (G allele frequency ~0.07%), but it shows a striking enrichment in Ashkenazi Jewish populations⁴⁴ enrichment in Ashkenazi Jewish populations
~1.56% G allele frequency in Ashkenazi Jewish individuals per gnomAD v4 exomes (26,134 samples), approximately 40-fold higher than in non-Jewish European populations; this pattern of Ashkenazi enrichment is shared by several other rare NOD2 variants and is consistent with founder effects in that population.

The Mechanism

The N852S substitution sits within the NOD2 leucine-rich repeat domain, the same region disrupted by all three major Crohn's disease NOD2 mutations (R702W, G908R, L1007fs). The LRR domain directly senses bacterial muramyl dipeptide (MDP), a peptidoglycan fragment shed by virtually all bacteria. When NOD2 binds MDP, it activates NF-κB⁵⁵ activates NF-κB
the canonical inflammatory transcription factor; NOD2-mediated NF-κB activation drives expression of antimicrobial peptides (defensins), cytokines, and chemokines that coordinate the mucosal immune response and triggers antimicrobial defenses. LRR domain missense variants impair this MDP-sensing step.

Functional studies of Crohn's-associated NOD2 variants demonstrate that LRR-domain missense changes share a common signaling defect — reduced NF-κB activation in response to bacterial ligands⁶⁶ LRR-domain missense changes share a common signaling defect — reduced NF-κB activation in response to bacterial ligands
despite retaining MDP-binding capacity, the variants fail to efficiently transduce the downstream signal; Hsp70 chaperone interaction can partially restore function, suggesting the variants cause conformational instability rather than complete loss of ligand recognition. The net consequence is reduced output of alpha-defensins (HD-5 and HD-6)⁷⁷ alpha-defensins (HD-5 and HD-6)
antimicrobial peptides secreted by Paneth cells in the ileal crypts; defensin deficiency allows bacterial dysbiosis in the terminal ileum from the ileal Paneth cells that express NOD2 at the highest levels in the body.

When NOD2 fails to properly clear and contain gut bacteria, a second consequence emerges: impaired cross-regulation of Toll-like receptor signaling⁸⁸ Toll-like receptor signaling
NOD2 normally dampens TLR2/4 activation by gut commensals; when NOD2 is weakened, the TLR-driven inflammatory axis runs less regulated, predisposing the mucosa to dysregulated cytokine release. The result is a mucosal environment that oscillates between inadequate microbial clearance and excessive inflammatory signaling — the dual defect underlying Crohn's disease pathogenesis.

The Evidence

The three major NOD2 Crohn's disease variants have been extensively characterized. In a meta-analysis of 75 case-control studies⁹⁹ meta-analysis of 75 case-control studies
18,727 CD cases and 17,102 controls; Yazdanyar et al. 2009, the per-allele odds ratios were: R702W (OR 2.2), G908R (OR 2.6), and L1007fs (OR 3.8), with compound heterozygotes carrying OR 9.0 for Crohn's disease. These are among the largest effect sizes documented for any common complex disease.

rs104895467 (N852S) is a rare variant not individually characterized in most large association studies, but is annotated in ClinVar with an "Association" relationship to regional enteritis (Crohn's disease). Structurally, it falls in the same LRR sensing domain as the three established risk variants, and deep resequencing studies¹⁰¹⁰ deep resequencing studies
Rivas et al. 2011; pooled resequencing of 56 IBD-associated genes across 16,054 CD cases, 12,153 UC cases, and 17,575 controls have established that the NOD2 LRR domain harbors multiple rare variants with independent disease associations beyond the three classical mutations.

The striking enrichment of this variant in Ashkenazi Jewish populations (~40-fold above non-Jewish European frequency) is clinically relevant: Ashkenazi Jewish individuals have elevated rates of Crohn's disease, and NOD2 variants appear to contribute disproportionately to this risk. The N852S frequency in this population (1.56%) means carrier status is not uncommon among Ashkenazi Jewish individuals reporting gastrointestinal symptoms.

NOD2 variants as a class predict a specific disease phenotype: a meta-analysis of 49 studies¹¹¹¹ meta-analysis of 49 studies
8,893 subjects with 2,897 NOD2 mutation carriers; Adler et al. 2011 found that NOD2 mutations increase the risk of complicated (stricturing or fistulizing) Crohn's disease by 33% compared to NOD2 wild-type patients. NOD2 variant carriers are specifically at risk for ileal disease — the segment where NOD2 is most highly expressed and Paneth cell antimicrobial function is most dependent on NOD2 signaling.

Practical Implications

Carrying one copy of the G allele (AG genotype) means one of your two NOD2 copies has a leucine-rich repeat domain change that may impair MDP sensing and NF-κB activation. Your other NOD2 copy remains functional. The primary clinical implication is vigilance for Crohn's disease symptoms — especially those pointing to the terminal ileum — and early evaluation when symptoms arise.

Since impaired NOD2 signaling affects ileal Paneth cell function and microbiome composition¹²¹² ileal Paneth cell function and microbiome composition
NOD2-deficient intestinal epithelium shows increased colonization by Enterobacteriaceae and reduced Firmicutes diversity, particularly in the ileum, strategies that support gut microbial diversity are specifically relevant for NOD2 variant carriers.

Interactions

N852S belongs to the class of LRR-domain NOD2 variants that, when present alongside a second NOD2 risk allele on the opposite chromosome (compound heterozygosity), produce a markedly elevated risk profile — the OR of ~9.0 for compound heterozygotes documented in the Yazdanyar 2009 meta-analysis applies to biallelic NOD2 states generally. If rs104895467 is carried alongside rs2066844 (R702W, OR 2.2), rs2066845 (G908R, OR 2.6), or rs2066847 (L1007fs, OR 3.8) on the other chromosome, the combined risk profile requires clinical attention.

NOD2 also interacts with ATG16L1 rs2241880¹³¹³ ATG16L1 rs2241880
the T300A autophagy variant that cooperates with NOD2 in bacterial clearance via selective autophagy (xenophagy); carriers of both NOD2 and ATG16L1 risk alleles show additive impairment of intestinal bactericidal function. The downstream NF-κB pathway shared by NOD2 and TNFAIP3¹⁴¹⁴ TNFAIP3
the A20 deubiquitinase that terminates NOD2-triggered NF-κB signaling; A20 loss-of-function variants can amplify the baseline inflammatory state in NOD2 risk carriers represents another axis where variants compound.

OCTN1¹¹ OCTN1
Organic Cation Transporter Novel 1 — a membrane transport protein expressed in the intestine, kidney, liver, lung, and immune cells that shuttles organic cations and the dietary antioxidant ergothioneine into cells is the product of the SLC22A4 gene on chromosome 5q31. The region around SLC22A4 is one of the earliest and most replicated inflammatory bowel disease susceptibility loci in human genetics — a 250 kb haplotype block called the IBD5 locus²² IBD5 locus
A linkage-disequilibrium block on chromosome 5q31 first identified in a Canadian sib-pair study of Crohn's disease; the locus spans SLC22A4, SLC22A5, and several immune-regulatory genes including IRF1 and IL5. The L503F missense variant in OCTN1 is one of two functional variants proposed to underlie the IBD5 risk haplotype, the other being rs2631367 (-207G>C) in the SLC22A5 (OCTN2) promoter.

The Mechanism

OCTN1 uses a sodium gradient to transport ergothioneine³³ ergothioneine
A naturally occurring amino acid synthesized only by fungi and some bacteria; humans obtain it entirely from diet, primarily through mushrooms, oats, and black beans; OCTN1 is the dedicated mammalian ergothioneine transporter into cells. The L503F substitution — a leucine-to-phenylalanine swap in the 11th transmembrane domain — meaningfully alters the transporter's kinetic profile.

Gründemann et al. showed⁴⁴ Gründemann et al. showed
PNAS 2009 — the 503F variant has 3-fold higher substrate affinity (lower Km) and 2-fold lower maximal transport velocity (Vmax) for ergothioneine, yielding 50% higher net transport efficiency at the physiological ergothioneine concentrations found in food and portal blood. The result: 503F carriers (CT and TT) accumulate higher ergothioneine concentrations in OCTN1-expressing tissues — including intestinal epithelium, macrophages, and neutrophils — than 503L homozygotes (CC) eating the same diet. In parallel, the 503F variant shows reduced carnitine transport (2.7-fold lower uptake) and altered uptake of various organic cations.

The functional paradox is that 503F is an ergothioneine gain-of-function variant associated with increased inflammatory disease risk. Current evidence suggests the primary causal signal at IBD5 may reside in nearby variants near IRF1 (Interferon Regulatory Factor 1)⁵⁵ Current evidence suggests the primary causal signal at IBD5 may reside in nearby variants near IRF1 (Interferon Regulatory Factor 1)
Festen et al., Nature Genetics 2011 — reanalysis of IBD5 suggested that 503F may be a recent European-enriched adaptation that swept to high frequency in linkage disequilibrium with the true causal signal, rather than being causal itself. Regardless of causality, the T allele remains a reliable risk tag for the IBD5 haplotype.

The Evidence

Peltekova et al.⁶⁶ Peltekova et al.
Nature Genetics 2004 — first proposed the two-locus IBD5 TC haplotype (SLC22A4 L503F-T + SLC22A5 -207C) as functional Crohn's disease risk variants; TC heterozygotes showed OR 2.1–2.56; TC/TC homozygotes showed OR 3.43–5.14 in two independent Canadian cohorts. This seminal finding made the IBD5 TC haplotype one of the best-replicated Crohn's disease susceptibility signals in the pre-GWAS era.

Subsequent replication studies confirmed the association in European cohorts. Noble et al., Gastroenterology 2005⁷⁷ Noble et al., Gastroenterology 2005
Studied TC haplotype in 1,400 Crohn's disease patients and 725 controls; TC/TC homozygotes were more likely to require intestinal resection and had higher rates of stricturing or penetrating disease, establishing a genotype-severity relationship beyond susceptibility alone.

Population data are striking: the T allele reaches 42% in European-Americans but drops to approximately 2% in East Asians, consistent with the observation that the IBD5 association with Crohn's disease is not observed in Japanese populations. This European enrichment has been proposed to reflect a recent selective sweep in European ancestry, possibly related to dietary adaptation to mushroom-rich environments.

Practical Actions

For TT homozygotes — carrying two copies of the 503F allele — the OCTN1 transporter accumulates particularly high ergothioneine tissue concentrations. The clinical significance is primarily as a tag for the IBD5 risk haplotype: elevated Crohn's disease susceptibility, with evidence that disease course may be more severe. Monitoring for early gastrointestinal symptoms and optimizing the gut microbiome through diet are the most actionable responses.

Because OCTN1 also regulates carnitine transport (with 503F reducing carnitine uptake 2.7-fold in vitro), TT homozygotes may have modestly reduced intestinal carnitine absorption. Carnitine status can be supported through dietary sources (red meat, dairy) or supplementation.

Interactions

The T allele at rs1050152 is the primary coding component of the IBD5 TC haplotype. Its partner variant, rs2631367 (-207G>C in the SLC22A5/OCTN2 promoter), reduces OCTN2 expression and synergizes with L503F to confer full TC haplotype risk for Crohn's disease. TC/TC homozygotes — those carrying the T allele here AND the C allele at rs2631367 — show the highest disease risk (OR 3.43–5.14) in the original Peltekova data. Single-locus carriage at either site confers intermediate risk.

Downstream of IBD5, NOD2/CARD15 variants (rs2066844, rs2066845, rs2066847) act in a common pathogenic pathway with the OCTN haplotype; compound carriage of IBD5 TC haplotype plus NOD2 variants may substantially further elevate Crohn's disease risk.

When a blood vessel wall becomes injured or inflamed, one of the body's first responders is the leukotriene pathway¹¹ leukotriene pathway
a branch of arachidonic acid metabolism that produces potent lipid-based inflammatory mediators from immune cells. ALOX5AP — arachidonate 5-lipoxygenase activating protein, also called FLAP (5-lipoxygenase activating protein) — is the essential scaffold protein that anchors the enzyme 5-lipoxygenase to the nuclear membrane, enabling it to convert arachidonic acid into leukotrienes. Without ALOX5AP, leukotriene biosynthesis essentially stops. Variants in ALOX5AP alter how much leukotriene the body makes when challenged by vascular stress, with downstream consequences for atherosclerosis, thrombosis, and stroke risk.

The Mechanism

rs10507391 is an intronic variant in ALOX5AP on chromosome 13q12 and is one of the four tagging SNPs that define the HapA haplotype²² HapA haplotype
a four-SNP risk haplotype in ALOX5AP first identified by deCODE Genetics in Iceland. The HapA haplotype is not a protein-coding change — it alters gene regulation and mRNA expression levels rather than the ALOX5AP protein sequence directly.

The A allele at rs10507391 has a cis-effect on ALOX5AP transcript levels and exerts trans-effects on expression of downstream pathway members ALOX5 and LTA4H in human aortic tissue samples with varying degrees of atherosclerosis. Crosslin et al., Human Genetics 2009³³ Crosslin et al., Human Genetics 2009 demonstrated that rs10507391 genotype significantly predicts expression across multiple leukotriene pathway nodes simultaneously — a signature of a regulatory hub variant influencing the entire biosynthetic axis.

The biological consequence: stimulated immune cells (neutrophils, monocytes) from A-allele carriers produce greater quantities of leukotriene B4 and cysteinyl leukotrienes. These are potent chemoattractants and vasoconstrictors that drive macrophage infiltration into atherosclerotic plaques, promote endothelial activation, and destabilize lipid cores — processes central to both plaque formation and acute thrombotic events.

The Evidence

The foundational study, Helgadottir et al., Nature Genetics 2004⁴⁴ Helgadottir et al., Nature Genetics 2004
deCODE Genetics, Iceland, identified the four-SNP ALOX5AP haplotype (HapA, which includes the rs10507391 A allele) as associated with approximately two-fold increased risk of myocardial infarction and stroke in an Icelandic population. Critically, the excess leukotriene B4 production in neutrophils was observed specifically in males carrying the at-risk haplotype, establishing a plausible sex-modulated biological mechanism.

Meta-analytic evidence for ischemic stroke has been mixed. A Caucasian-focused meta-analysis of 9 studies (4,198 cases, 3,699 controls)⁵⁵ Caucasian-focused meta-analysis of 9 studies (4,198 cases, 3,699 controls)
Li et al., Cell Mol Biol 2017 found significant association of rs10507391 with ischemic stroke risk (OR=1.18; 95% CI 1.08–1.28; P=0.0002), with the European subgroup showing OR=1.20. A larger, broader meta-analysis of 30 studies (32,782 participants)⁶⁶ broader meta-analysis of 30 studies (32,782 participants)
Zheng et al., Neuropsychiatr Dis Treat 2019 found no significant association overall (OR=1.03; 95% CI 0.93–1.14; P=0.557). This divergence likely reflects population stratification (the original Icelandic signal was ancestry-specific), haplotype-level effects not captured by single-SNP analysis, and interaction effects missed in pooled analyses.

The most mechanistically compelling validation comes from the European EUSTAR scleroderma cohort⁷⁷ European EUSTAR scleroderma cohort
Kowal-Bielecka et al., Rheumatology 2017 (977 SSc patients, 558 controls), where A-allele carriers at rs10507391 showed directly measured increases in cysteinyl leukotriene production from peripheral blood mononuclear cells. The variant associated with SSc susceptibility (OR=1.27; 95% CI 1.07–1.50) and, more strongly, with SSc-related interstitial lung disease (OR=1.45; 95% CI 1.17–1.79). This direct functional measurement of leukotriene excess provides mechanistic validation of the original Icelandic biological hypothesis.

A gene-gene interaction study in Chinese populations (Chi et al., Neuroreport 2014)⁸⁸ (Chi et al., Neuroreport 2014) found no individual effect of rs10507391 in isolation but a significant interaction with CYP3A5 A6986G that increased cerebral infarction risk nearly twofold (OR=1.80; 95% CI 1.18–2.76; P=0.006) — reinforcing the pattern that this variant's clinical impact depends heavily on genetic and environmental context.

Practical Actions

For AT heterozygotes, the primary action is monitoring inflammatory cardiovascular biomarkers — particularly high-sensitivity CRP, which integrates vascular inflammatory activity broadly and can motivate targeted lipid or anti-inflammatory therapy earlier than standard guidelines suggest.

For AA homozygotes, the evidence supports a more proactive approach: leukotriene-modulated inflammation is a distinct pathway from LDL-driven atherosclerosis, and conventional lipid management alone may not address it. Dietary shifts toward omega-3 fatty acids — specifically EPA (eicosapentaenoic acid), which competitively reduces leukotriene B4 synthesis — provide a mechanism-specific intervention. The 5-lipoxygenase pathway is also inhibited by flavonoids abundant in dark berries, quercetin-rich foods, and certain culinary herbs.

Smoking is particularly relevant here: smoking amplifies leukotriene production and synergizes with ALOX5AP genetic variation to increase atherosclerotic stroke risk in published interaction studies.

Interactions

rs10507391 is one of four tagging SNPs in the ALOX5AP HapA haplotype. The other HapA-defining SNPs (rs4769874, rs9551963, rs9315050, rs4147064) are all within ALOX5AP and collectively define the at-risk regulatory state — risk is maximal when multiple HapA alleles co-occur. HapA haplotype analysis consistently shows larger effects than any single tagging SNP analyzed alone.

A gene-gene interaction between rs10507391 and CYP3A5 rs776746 has been documented in cerebral infarction, with combined OR of ~1.80. CYP3A5 is involved in arachidonic acid metabolism, creating two-pathway convergence on leukotriene-mediated vascular inflammation. Individuals carrying risk alleles at both loci should be flagged for comprehensive cardiovascular inflammatory workup.

Pathway-level interactions with LTA4H (leukotriene A4 hydrolase, which converts the ALOX5AP product LTA4 into LTB4) and LTC4S (leukotriene C4 synthase, producing cysteinyl leukotrienes) have been documented — see related SNPs rs17222814 (LTA4H) and leukotriene receptor variants.

The glucocorticoid receptor encoded by NR3C1 is the cell's primary transducer of cortisol signaling — connecting the body's stress response to gene expression programs that regulate inflammation, metabolism, immune function, and cellular aging. Most NR3C1 variants studied to date alter GR sensitivity in ways that affect stress-related disease risk. This intronic variant (rs10515522) takes a different angle: it was discovered not through a disease study but through a longevity study, comparing the genomes of Polish nonagenarians and centenarians to those of newborn controls.

The signal is independent of the two other NR3C1 variants already catalogued in this database — rs6198 (9β)¹¹ rs6198 (9β), which alters GRβ isoform expression and blunts cortisol signaling, and rs41423247 (BclI)²² rs41423247 (BclI), which increases glucocorticoid sensitivity. rs10515522 sits in a different region of the gene and appears to exert its effect through a distinct mechanism, most likely regulatory rather than structural.

The Mechanism

rs10515522 is an intron variant at chromosome 5 position 143,378,829 (GRCh38). NR3C1 spans the minus strand of chromosome 5, so the T reference allele on the plus strand corresponds to an A on the coding strand, and the C alternate allele corresponds to a G. The variant has no known protein-coding consequence; its effect, if any, is likely on transcription regulation, splicing efficiency, or post-transcriptional processing of NR3C1 transcripts.

A 2018 haplotype study³³ 2018 haplotype study
Plieger T et al. NR3C1 and NR3C2 variation in cortisol response and cognition under acute stress. Psychoneuroendocrinology, 2017 included rs10515522 in a panel of 10 NR3C1 SNPs and found that the composite NR3C1 haplotype significantly predicted cortisol reactivity (p = 0.011) during acute stress challenge in 126 healthy males. rs10515522's contribution to the haplotype-level effect was not individually resolved, but its inclusion in the panel is consistent with the variant having regulatory influence on GR expression or activity.

The CC genotype's association with elevated total cholesterol⁴⁴ CC genotype's association with elevated total cholesterol
Olczak E et al., 2019 provides an additional functional clue: glucocorticoids directly regulate hepatic lipoprotein metabolism through GR-mediated transcription of cholesterogenic genes. Altered NR3C1 expression or splicing in liver tissue could plausibly shift the set point of glucocorticoid- driven cholesterol synthesis.

The Evidence

The primary evidence comes from a Polish centenarian cohort study. Olczak et al. (2019)⁵⁵ Olczak et al. (2019)
Glucocorticoid receptor gene polymorphisms are associated with age and blood parameters in Polish Caucasian nonagenarians and centenarians. Experimental Gerontology, 116:20-24 genotyped three NR3C1 variants (rs10515522, rs2963154, rs2918418) in 552 individuals aged 95-106 years from Polish Caucasian ancestry, compared against 284 cord blood samples from newborn controls.

Two findings are reported for rs10515522. In the cross-sectional comparison, the TT genotype was more prevalent in the long-lived group (p = 0.016) — a finding that must be interpreted carefully given that TT is simply the most common genotype overall (~71% European frequency). The more mechanistically informative finding is the survival analysis: carriers of the C minor allele (TC and CC combined, or possibly TC alone) had significantly better survival rates within the elderly cohort. This longitudinal signal — who survives longer after already reaching age 95 — is the stronger evidence of a longevity effect.

Additionally, the CC homozygous genotype was associated with elevated total cholesterol (p = 0.049), suggesting that two copies of the C allele shifts NR3C1 activity in a direction that affects hepatic lipid metabolism — a finding that echoes the effect also seen for rs2963154 in the same study.

The evidence level is emerging: this is a single cohort study with a moderate sample size. No independent replication of rs10515522's longevity association has been published. The biological mechanism remains speculative. However, the study's design — nonagenarians and centenarians are a gold-standard extreme-longevity phenotype — and its internal consistency across multiple NR3C1 variants give it more weight than a typical single-study finding.

Practical Implications

The longevity association of rs10515522 suggests that NR3C1 regulation in late life has measurable survival consequences. Given cortisol's central role in the biology of aging — mediating cellular senescence through glucocorticoid-driven atrophy of tissues including immune cells, hippocampal neurons, and skeletal muscle — variants that alter the GR's activity level or tissue-specific expression are plausibly relevant to healthspan and lifespan.

For TC carriers, the survival benefit observed in the centenarian cohort suggests that a single copy of the C allele may confer some advantage in maintaining GR-mediated adaptation into advanced age. For CC carriers, the cholesterol association introduces a clinically relevant consideration: lipid monitoring is warranted regardless of other risk factors, since altered GR activity in the liver may shift cholesterol metabolism independent of diet and lifestyle.

For TT carriers (the large majority), no specific longevity disadvantage is established by this single study, but the absence of the C allele means they don't share the survival benefit observed in the elderly cohort.

Interactions

rs10515522 operates within the same NR3C1 gene as rs6198 (9β)⁶⁶ rs6198 (9β) and rs41423247 (BclI)⁷⁷ rs41423247 (BclI). The three variants likely contribute to a composite NR3C1 haplotype that determines overall GR function. The haplotype study by Plieger et al. (2018) specifically examined rs10515522 alongside rs6198, rs41423247, and seven other NR3C1 SNPs, finding that the composite haplotype predicts cortisol reactivity more reliably than any single variant.

rs2963154, studied alongside rs10515522 in the longevity cohort, showed a similar but stronger effect (p = 0.002 for TT enrichment in centenarians) and associated with both total and HDL cholesterol. The two variants may tag the same or overlapping regulatory elements in the NR3C1 intron.

FKBP5 (rs1360780), a glucocorticoid receptor co-chaperone variant, would compound with any NR3C1 functional variant affecting HPA axis regulation, though no direct interaction data for rs10515522 specifically has been published.

Within a narrow region of chromosome 15 sits one of the most replicated genetic signals for smoking behavior ever discovered. The CHRNA3/CHRNA5/CHRNB4 gene cluster encodes three subunits of the nicotinic acetylcholine receptor (nAChR)—the molecular target of nicotine—and variants within it have been identified as the strongest genetic determinants of cigarette consumption, nicotine dependence, and smoking-related disease. rs1051730 is a synonymous variant in CHRNA3 (encoding no amino acid change at position 215) that nonetheless emerged from the largest smoking genetics consortium ever assembled¹¹ the largest smoking genetics consortium ever assembled
The TAG Consortium pooled over 74,000 participants and found rs1051730 to be the top signal for cigarettes per day at genome-wide significance: beta=1.03 cigarettes/day, p=2.8×10⁻⁷³ as the region's top marker for smoking quantity.

The variant does not change the CHRNA3 protein, but it sits in near-perfect linkage disequilibrium (LD)²² linkage disequilibrium (LD)
Two variants are in LD when they are so frequently inherited together that one effectively predicts the other; r²=1 means perfect co-inheritance in that population with rs16969968 in the neighboring CHRNA5 gene among people of European ancestry (r²≈1). In European populations, carrying the A allele at rs1051730 almost certainly means carrying the risk allele at rs16969968 as well—making it difficult to disentangle their individual contributions. However, because LD patterns differ across ancestral populations, rs1051730 and rs16969968 are not equivalent in all groups. In African Americans³³ African Americans
Two independent studies found rs1051730 associated with lung cancer risk (OR=1.59–1.81) in African Americans, where the variant may operate partly independently of rs16969968, the two variants show different frequencies and patterns of co-inheritance, making rs1051730 informative as a distinct signal.

The Mechanism

Because rs1051730 is synonymous, it does not directly alter the alpha-3 subunit's amino acid sequence. Its associated biological effects are thought to be primarily mediated through LD with rs16969968, which produces the Asp398Asn missense change in CHRNA5 and reduces alpha-5 nicotinic receptor function by approximately 50%. However, recent evidence suggests the region may also contain additional cis-regulatory variants⁴⁴ additional cis-regulatory variants
rs2036527 has been identified as an independent enhancer variant that regulates both CHRNA3 and CHRNA5 expression via chromatin looping, ChIP, and luciferase assays controlling gene expression levels of both CHRNA3 and CHRNA5, complicating the simple picture that rs16969968 alone explains all risk.

Nicotinic acetylcholine receptors containing the alpha-3 subunit are concentrated in the medial habenula, interpeduncular nucleus, and peripheral ganglia. These receptors govern two critical functions: the brain's aversive response to high nicotine doses (the natural brake on excessive smoking) and peripheral regulation of heart rate, lung function, and vascular tone. Reduced receptor function in this pathway weakens the signal that normally limits nicotine intake—allowing heavy smoking to develop without generating proportionally stronger aversion. The variant also modulates nicotine's effect on sensorimotor gating⁵⁵ modulates nicotine's effect on sensorimotor gating
In a controlled pharmacology study, TT homozygotes showed significant prepulse inhibition enhancement with nicotine while TC/CC carriers tended toward worsening—indicating genotype-dependent attentional responses to nicotine, a measure of attentional filtering relevant to attentional disorders and psychosis vulnerability.

The Evidence

The association with smoking quantity is among the most replicated findings in behavioral genetics. The TAG Consortium meta-analysis⁶⁶ TAG Consortium meta-analysis
Tobacco and Genetics Consortium pooled 74,053 European-ancestry participants from 16 genome-wide association studies found rs1051730[A] associated with approximately 1 extra cigarette per day per allele copy (beta=1.03, p=2.8×10⁻⁷³). Among heavy versus light smokers, the A allele confers OR≈1.34 (95% CI 1.21–1.49).

Lung disease risk is substantial and cumulative. A large population study of 57,657 Danes⁷⁷ large population study of 57,657 Danes
The Copenhagen General Population Study prospectively examined rs1051730 in 34,592 ever-smokers with spirometry and disease follow-up found that AA homozygotes had significantly reduced lung function (FEV₁ 94.1% predicted vs 96.5% in GG), a 70% higher risk of severe COPD (OR=1.7 for GOLD III-IV), and an 80% higher risk of lung cancer (OR=1.8) compared to GG noncarriers—a dose-dependent pattern where AG heterozygotes fell in between. These associations persisted after adjusting for cumulative tobacco consumption, suggesting effects beyond smoking quantity alone.

Lung cancer risk across diverse populations has been confirmed in multiple cohorts⁸⁸ multiple cohorts
A meta-analysis of 38 studies concluded that rs1051730 is associated with elevated lung cancer risk across Caucasian, African American, and Asian populations. Critically, in African Americans, where rs1051730 and rs16969968 are not in perfect LD, two independent studies found lung cancer ORs of 1.59–1.81⁹⁹ two independent studies found lung cancer ORs of 1.59–1.81
Amos et al. (OR=1.81, p=.001) and Schwartz et al. (OR=1.59, CI 1.16–2.19) both found significant lung cancer associations in African Americans; notably, these effects were "only weakly associated with smoking phenotypes," suggesting a direct carcinogenic pathway beyond nicotine behavior, with effects that were "only weakly associated with smoking phenotypes"—pointing to a potentially direct carcinogenic pathway beyond simply smoking more.

Cognitive effects have been documented but are modest. rs1051730 was among three CHRNA cluster SNPs¹⁰¹⁰ rs1051730 was among three CHRNA cluster SNPs
Among the WAIS-R cognitive battery, rs16969968 and rs1051730 were both associated with working memory performance on n-back tasks and the Continuous Performance Test in a European sample associated with working memory performance, verbal reasoning, and processing speed. This suggests the variant's effects on nicotinic signaling extend to everyday cognitive function, and may partly explain why nicotine acutely enhances attention in dependent smokers.

For smoking cessation, rs1051730 shows a weak association with short-term quit rates¹¹¹¹ a weak association with short-term quit rates
Meta-analysis of two UK clinical trials in treatment-seeking smokers found association at 4-week follow-up but not at longer intervals; effect was independent of NRT type and not explained by dependence severity alone. The effect appears modest and is not robust at longer follow-up intervals, suggesting the genotype is more relevant for understanding dependence than for predicting cessation success with current treatments.

Practical Actions

Carrying the A allele at rs1051730 signals elevated risk for developing heavy nicotine dependence and for smoking-related lung disease. In European-ancestry individuals, this is largely equivalent to carrying the CHRNA5 rs16969968 risk allele, and the practical guidance is similar: avoid initiating tobacco use, pursue intensive cessation support if smoking, and consider earlier lung cancer screening with adequate smoking history.

In individuals of African, South Asian, or Latino ancestry, rs1051730 may convey additional independent information beyond rs16969968, particularly for lung cancer risk. The population-stratified data suggest the variant's lung cancer association in African Americans may not be fully explained by smoking behavior, warranting vigilance even among lighter smokers or former smokers.

For patients with cognitive concerns or attention-related symptoms, understanding that nicotinic receptor genetics influences working memory and sensorimotor gating adds context—though no specific cognitive interventions are currently evidence-based for this genotype.

Interactions

In European-ancestry individuals, rs1051730 and rs16969968 (CHRNA5) are in near-perfect LD (r²≈1), meaning they almost always co-occur. They are effectively tagging the same haplotype, and carrying risk alleles at both positions simultaneously provides no additional independent risk assessment for Europeans. For non-European individuals, particularly those of African ancestry, the LD between the two variants is incomplete, making both variants informative as distinct signals.

The broader CHRNA5-CHRNA3-CHRNB4 cluster contains additional associated variants including rs578776, rs8034191 (AGPHD1), and rs6495309. The regulatory variant rs2036527 has been recently identified as a functional cis-eQTL controlling expression of both CHRNA3 and CHRNA5, and may partially explain associations attributed to rs1051730 through expression-level rather than coding-level mechanisms.

rs1051730's cognitive associations overlap with those of rs16969968 and may reflect the same underlying effect on nicotinic receptor function—weakening attention-modulating cholinergic signaling that normally supports working memory and sensory gating.